Financial Report: Johnson & Johnson 4Q

Johnson & Johnson 4Q

4Q Revenues: $16.6 billion (+9%)

4Q Earnings: $2.2 billion (-19%)

FY Revenues: $61.9 billion (-3%)

FY Earnings: $12.3 billion (-5%)

Comments: Worldwide Pharmaceutical sales were $22.5 billion for the year (-8%), while Worldwide Medical Devices and Diagnostics sales were $23.6 billion for year (+2%). Products with operational growth for the year included: Remicade, Prezista, Velcade, Risperdal, Consta. Sales of Topamax and Risperdal were negatively impacted by generic competition. U.S. Pharma sales were down 3% in 4Q09 to $3.3 billion, and were down 12% in FY09 to $13 billion. Worldwide Consumer sales were $15.8 billion for the year (-2%).